Novel trends in orphan market drug discovery amyotrophic lateral sclerosis as a case study

10.2741/a762 ◽  
2002 ◽  
Vol 7 (3) ◽  
pp. c83-96
Author(s):  
Jennifer E Clark
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Drug Discovery ◽  
Lateral Sclerosis

Simple animal models for amyotrophic lateral sclerosis drug discovery

2016 ◽  
Vol 11 (8) ◽  
pp. 797-804 ◽  
Author(s):  
Shunmoogum A. Patten ◽  
J. Alex Parker ◽  
Xiao-Yan Wen ◽  
Pierre Drapeau
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Drug Discovery ◽  
Animal Models ◽  
Lateral Sclerosis

A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis

Neurocase ◽  
2020 ◽  
pp. 235-247
Author(s):  
Anli Liu ◽  
Kelly Werner ◽  
Subhojit Roy ◽  
John Q. Trojanowski ◽  
Ursula Morgan-Kane ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Frontotemporal Lobar Degeneration ◽  
Visual Artist ◽  
Lateral Sclerosis

A Case Study on the Use of Trihexyphenidyl, Korean Medical Treatment for the Control of Sialorrhea in Patients with Amyotrophic Lateral Sclerosis(ALS)

2013 ◽  
Vol 30 (2) ◽  
pp. 73-79 ◽  
Author(s):  
Ho Hyun Jeong ◽  
Sung Ha Kim ◽  
Sang Mi Lee ◽  
Jong Chul Lee ◽  
Man Young Park ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Medical Treatment ◽  
Lateral Sclerosis

scholarly journals From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies

Molecules ◽  
2020 ◽  
Vol 25 (15) ◽  
pp. 3320
Author(s):  
Serge Mignani ◽  
Jean-Pierre Majoral ◽  
Jean-François Desaphy ◽  
Giovanni Lentini
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Structural Analog ◽  
Interesting Case ◽  
Scaffold Hopping ◽  
Disease Treatment ◽  
Benzothiazole Derivatives ◽  
Great Hope ◽  
Diagnostic Agents ◽  
Lateral Sclerosis

The 1,3-benzothiazole (BTZ) ring may offer a valid option for scaffold-hopping from indole derivatives. Several BTZs have clinically relevant roles, mainly as CNS medicines and diagnostic agents, with riluzole being one of the most famous examples. Riluzole is currently the only approved drug to treat amyotrophic lateral sclerosis (ALS) but its efficacy is marginal. Several clinical studies have demonstrated only limited improvements in survival, without benefits to motor function in patients with ALS. Despite significant clinical trial efforts to understand the genetic, epigenetic, and molecular pathways linked to ALS pathophysiology, therapeutic translation has remained disappointingly slow, probably due to the complexity and the heterogeneity of this disease. Many other drugs to tackle ALS have been tested for 20 years without any success. Dexpramipexole is a BTZ structural analog of riluzole and was a great hope for the treatment of ALS. In this review, as an interesting case study in the development of a new medicine to treat ALS, we present the strategy of the development of dexpramipexole, which was one of the most promising drugs against ALS.

F09 Huntington disease and amyotrophic lateral sclerosis: a case study

2018 ◽  
Author(s):  
Clare Gibbons ◽  
Sherali Esmail ◽  
Harrison Mah ◽  
Wai Lun Alan Fung
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Huntington Disease ◽  
Lateral Sclerosis
Sign in / Sign up

Export Citation Format

Share Document